The global epigenetics market was valued at USD 772 Million in 2019, and is projected to reach USD 2,168 Million by 2027, registering a CAGR of 13.6% from 2020 to 2027.
Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics results in changes in phenotype of an organism rather than genotype, wherein underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could pass from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology.
The epigenetics market is anticipated to witness a significant market growth during the forecast period, owing to rise in prevalence of cancer, increase in funding for R&D activities, rise in partnership between academic, pharmaceutical, and biotechnology companies for epigenetics studies, and increase in application of epigenetics in non-oncology diseases majorly drives the market growth. However, high cost of instruments and lack of trained professionals are factors that impede the market growth. Furthermore, growth opportunities in emerging markets provide lucrative opportunities to the market players.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. Although there is no clinically approved drug or vaccine available to be used against coronavirus infection, few therapeutic combinations have been evaluated to survive this viral infection. Moreover, use of targeted antiviral therapies such as remdesivir, rapamycin, ribavirin, and other epigenetic drugs such as BRD4 inhibitors, DNMT1 inhibitors, and HDAC inhibitors have been demonstrated to potentially inhibit the virus function. Researchers have begun to understand how epigenetics may prevent viral proliferation so that vaccines and therapeutics can be developed to specifically target replicating mechanisms of a virus. Thus, rise in the number of epigenetic researches and growth in awareness of epigenetic drugs for treatment of coronavirus infection are anticipated to show overall positive impact on the epigenetics industry.
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits & assays, instruments, and reagents.
Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits are further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. On the basis of instruments, the market is categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. Reagents are further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is classified into oncology and non-oncology. Oncology is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is classified into academic & government research institutes, pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). Region wise, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of product, the kits & assays product segment occupied the highest share in the epigenetics market, owing to their sheer usage, need throughout the protocol, and other pre-requisite steps of DNA analysis. Some other factors such as increase in aging population, rise in incidences of chronic diseases, and growth in adoption of epigenetic procedures boost demand for epigenetic kits, which drives the market growth for kits. Moreover, development of advanced epigenetic procedures and increase in the number of strategic developments by key players are expected to provide numerous opportunities in the future.
On the basis of application, the oncology segment dominated the application segment in 2019. Increase in adoption of epigenetics for oncology, higher number of R&D activities, and availability of a wide variety of products majorly fuel the market growth. Epigenetics is used to study development of cancers by observing changes in normal cells that undergo malignant transformation. Moreover, epigenetic modifications can also be used to select potential biomarkers, anticancer therapies, and reasonable dosages of anticancer drugs.
Asia-Pacific presents lucrative opportunities for key players operating in the epigenetics market, owing to growth in awareness about epigenetics, development of the R&D sector, and surge in penetration of key players in Asia-Pacific. In addition, increase in use of epigenetics for various applications has led to rapid developments in the industry.
The key players profiled in this report include Abcam Plc., Active Motif, Inc., Agilent Technologies, Inc., Diagenode, Illumina Inc., Merck Millipore, PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Zymo Research.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top player positioning, 2019
3.2.3.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Technological advancements associated with epigenetics
3.4.1.2.Increase in incidences of cancer
3.4.1.3.Increase in genome mapping programs
3.4.1.4.Increase in number of R&D activities
3.4.2.Restraints
3.4.2.1.Standardization concerns over epigenetics-based diagnostics
3.4.2.2.Dearth of skilled professionals
3.4.3.Opportunity
3.4.3.1.Growth opportunities in emerging markets
3.4.4.Impact analysis
3.5.COVID-19 impact analysis on epigenetics market
CHAPTER 4:EPIGENETICS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Kits
4.2.1.Key market trends growth factors and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.ChIP sequencing kits
4.2.2.1.1.Market size and forecast
4.2.2.2.Bisulfite conversion kits
4.2.2.2.1.Market size and forecast
4.2.2.3.Whole genome amplification kits
4.2.2.3.1.Market size and forecast
4.2.2.4.5-hmC & 5-mC Analysis Kits
4.2.2.4.1.Market size and forecast
4.2.2.5.RNA Sequencing Kits
4.2.2.5.1.Market size and forecast
4.2.2.6.Others
4.2.2.6.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Reagents
4.3.1.Key market trends growth factors and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Antibodies
4.3.2.1.1.Market size and forecast
4.3.2.2.Magnetic Beads
4.3.2.2.1.Market size and forecast
4.3.2.3.Histones
4.3.2.3.1.Market size and forecast
4.3.2.4.Buffers
4.3.2.4.1.Market size and forecast
4.3.2.5.Primers
4.3.2.5.1.Market size and forecast
4.3.2.6.Others
4.3.2.6.1.Market size and forecast
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Enzymes
4.4.1.Key market trends growth factors and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.DNA Polymerases
4.4.2.1.1.Market size and forecast
4.4.2.2.Other DNA-Modifying Enzymes
4.4.2.2.1.Market size and forecast
4.4.2.3.DNA Ligases
4.4.2.3.1.Market size and forecast
4.4.2.4.Methyltransferases
4.4.2.4.1.Market size and forecast
4.4.2.5.Acetylases
4.4.2.5.1.Market size and forecast
4.4.2.6.Reverse Transcriptase
4.4.2.6.1.Market size and forecast
4.4.2.7.Other protein-modifying enzymes
4.4.2.7.1.Market size and forecast
4.4.2.8.RNA Ligases
4.4.2.8.1.Market size and forecast
4.4.2.9.Other RNA-Modifying Enzymes
4.4.2.9.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Instruments
4.5.1.Key market trends growth factors and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Next generation sequencers
4.5.2.1.1.Market size and forecast
4.5.2.2.qPCRs
4.5.2.2.1.Market size and forecast
4.5.2.3.Mass Spectrometers
4.5.2.3.1.Market size and forecast
4.5.2.4.Sonicators
4.5.2.4.1.Market size and forecast
4.5.2.5.Others
4.5.2.5.1.Market size and forecast
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:EPIGENETICS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Oncology
5.2.1.Market size and forecast, by type
5.2.1.1.Solid Tumors
5.2.1.1.1.Market size and forecast
5.2.1.2.Liquid Tumors
5.2.1.2.1.Market size and forecast
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Non-oncology
5.3.1.Market size and forecast, by type
5.3.1.1.Metabolic diseases
5.3.1.1.1.Market size and forecast
5.3.1.2.Infectious diseases
5.3.1.2.1.Market size and forecast
5.3.1.3.Inflammatory diseases
5.3.1.3.1.Market size and forecast
5.3.1.4.Cardiovascular diseases
5.3.1.4.1.Market size and forecast
5.3.1.5.Others
5.3.1.5.1.Market size and forecast
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country
CHAPTER 6:EPIGENETICS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Academic & research institutes
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Pharmaceutical & biotechnology companies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Contract research organizations
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:EPIGENETICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, key growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. epigenetics market, by product
7.2.2.1.2.U.S. epigenetics market, by application
7.2.2.1.3.U.S. epigenetics market, by end user
7.2.2.2.Canada
7.2.2.2.1.Canada epigenetics market, by product
7.2.2.2.2.Canada epigenetics market, by application
7.2.2.2.3.Canada epigenetics market, by end user
7.2.2.3.Mexico
7.2.2.3.1.Mexico epigenetics market, by product
7.2.2.3.2.Mexico epigenetics market, by application
7.2.2.3.3.Mexico epigenetics market, by end user
7.2.3.North America market size and forecast, by Product
7.2.4.North America epigenetics market, by application
7.2.5.North America epigenetics market, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany epigenetics market, by product
7.3.2.1.2.Germany epigenetics market, by application
7.3.2.1.3.Germany epigenetics market, by end user
7.3.2.2.France
7.3.2.2.1.France epigenetics market, by product
7.3.2.2.2.France epigenetics market, by application
7.3.2.2.3.France epigenetics market, by end user
7.3.2.3.UK
7.3.2.3.1.UK epigenetics market, by product
7.3.2.3.2.UK epigenetics market, by application
7.3.2.3.3.UK epigenetics market, by end user
7.3.2.4.Italy
7.3.2.4.1.Italy epigenetics market, by product
7.3.2.4.2.Italy epigenetics market, by application
7.3.2.4.3.Italy epigenetics market, by end user
7.3.2.5.Spain
7.3.2.5.1.Spain epigenetics market, by product
7.3.2.5.2.Spain epigenetics market, by application
7.3.2.5.3.Spain epigenetics market, by end user
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe epigenetics market, by product
7.3.2.6.2.Rest of Europe epigenetics market, by application
7.3.2.6.3.Rest of Europe epigenetics market, by end user
7.3.3.Europe market size and forecast, by Product
7.3.4.Europe epigenetics market, by application
7.3.5.Europe epigenetics market, by end user
7.4.Asia-pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast
7.4.2.1.Japan
7.4.2.1.1.Japan epigenetics market, by product
7.4.2.1.2.Japan epigenetics market, by application
7.4.2.1.3.Japan epigenetics market, by end user
7.4.2.2.China
7.4.2.2.1.China epigenetics market, by product
7.4.2.2.2.China epigenetics market, by application
7.4.2.2.3.China epigenetics market, by end user
7.4.2.3.Australia
7.4.2.3.1.Australia epigenetics market, by product
7.4.2.3.2.Australia epigenetics market, by application
7.4.2.3.3.Australia epigenetics market, by end user
7.4.2.4.India
7.4.2.4.1.India epigenetics market, by product
7.4.2.4.2.India epigenetics market, by application
7.4.2.4.3.India epigenetics market, by end user
7.4.2.5.South Korea
7.4.2.5.1.South Korea epigenetics market, by product
7.4.2.5.2.South Korea epigenetics market, by application
7.4.2.5.3.South Korea epigenetics market, by end user
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific epigenetics market, by product
7.4.2.6.2.Rest of Asia-Pacific epigenetics market, by application
7.4.2.6.3.Rest of Asia-Pacific epigenetics market, by end user
7.4.3.Asia-Pacific market size and forecast, by Product
7.4.4.Asia-Pacific epigenetics market, by application
7.4.5.Asia-Pacific epigenetics market, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast
7.5.2.1.Latin America
7.5.2.1.1.Latin America epigenetics market, by product
7.5.2.1.2.Latin America epigenetics market, by application
7.5.2.1.3.Latin America epigenetics market, by end user
7.5.2.2.Middle East & Africa
7.5.2.2.1.Middle East & Africa epigenetics market, by product
7.5.2.2.2.Middle East & Africa epigenetics market, by application
7.5.2.2.3.Middle East & Africa epigenetics market, by end user
7.5.3.LAMEA market size and forecast, by Product
7.5.4.LAMEA epigenetics market, by application
7.5.5.LAMEA epigenetics market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.ABCAM PLC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ACTIVE MOTIF, INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.AGILENT TECHNOLOGIES, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.DIAGENODE DIAGNOSTICS
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.ILLUMINA, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.MERCK KGAA (MERCK MILLIPORE)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.PERKINELMER, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.QIAGEN N.V.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segment
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.THERMO FISHER SCIENTIFIC, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.ZYMO RESEARCH
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.EPIGENETICS KITS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 03.EPIGENETICS KITS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.EPIGENETICS REAGENTS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 05.EPIGENETICS REAGENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.EPIGENETICS ENZYMES MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.EPIGENETICS ENZYMES MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.EPIGENETICS INSTRUMENTS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 09.EPIGENETICS INSTRUMENTS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 10.EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 11.EPIGENETICS MARKET FOR ONCOLOGY, BY TYPE, 2019–2027 ($MILLION)
TABLE 12.EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2019–2027 ($MILLION)
TABLE 13.EPIGENETICS MARKET FOR NON-ONCOLOGY, BY TYPE, 2019–2027 ($MILLION)
TABLE 14.EPIGENETICS MARKET FOR NON-ONCOLOGY, BY REGION, 2019–2027 ($MILLION)
TABLE 15.EPIGENETICS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 16.EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2027 ($MILLION)
TABLE 17.EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2027 ($MILLION)
TABLE 18.EPIGENETICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2027 ($MILLION)
TABLE 19.EPIGENETICS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 22.U.S. EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 23.U.S. EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 24.CANADA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 25.CANADA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 26.CANADA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 27.MEXICO EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 28.MEXICO EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 29.MEXICO EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 30.NORTH AMERICA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 31.NORTH AMERICA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 32.NORTH AMERICA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 33.EUROPE EPIGENETICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 34.GERMANY EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 35.GERMANY EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 36.GERMANY EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 37.FRANCE EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 38.FRANCE EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 39.FRANCE EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 40.UK EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 41.UK EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 42.UK EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 43.ITALY EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 44.ITALY EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 45.ITALY EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 46.SPAIN EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 47.SPAIN EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 48.SPAIN EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 49.REST OF EUROPE EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 50.REST OF EUROPE EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 51.REST OF EUROPE EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 52.EUROPE EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 53.EUROPE EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 54.EUROPE EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 55.ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 56.JAPAN EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 57.JAPAN EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 58.JAPAN EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 59.CHINA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 60.CHINA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.CHINA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 62.AUSTRALIA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 63.AUSTRALIA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 64.AUSTRALIA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 65.INDIA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 66.INDIA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 67.INDIA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 68.SOUTH KOREA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 69.SOUTH KOREA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 70.SOUTH KOREA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 71.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 74.ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 75.ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 76.ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 77.LAMEA EPIGENETICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 78.LATIN AMERICA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 79.LATIN AMERICA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 80.LATIN AMERICA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 81.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 82.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 83.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 84.LAMEA EPIGENETICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 85.LAMEA EPIGENETICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 86.LAMEA EPIGENETICS MARKET, BY END USER, 2019–2027
TABLE 87.ABCAM: COMPANY SNAPSHOT
TABLE 88.ALLERGAN: PRODUCT PORTFOLIO
TABLE 89.ACTIVE MOTIF: COMPANY SNAPSHOT
TABLE 90.ACTIVE MOTIF: OERATING SEGMENT
TABLE 91.ACTIVE MOTIF: PRODUCT PORTFOLIO
TABLE 92.AGILENT: COMPANY SNAPSHOT
TABLE 93.AGILENT: OERATING SEGMENT
TABLE 94.AGILENT: PRODUCT PORTFOLIO
TABLE 95.DIAGENODE: COMPANY SNAPSHOT
TABLE 96.DIAGENODE: OPERATING SEGMENTS
TABLE 97.DIAGENODE: PRODUCT PORTFOLIO
TABLE 98.ILLUMINA: COMPANY SNAPSHOT
TABLE 99.ILLUMINA: OPERATING SEGMENTS
TABLE 100.ILLUMINA: PRODUCT PORTFOLIO
TABLE 101.MERCK: COMPANY SNAPSHOT
TABLE 102.MERCK: OPERATING SEGMENTS
TABLE 103.MERCK: PRODUCT PORTFOLIO
TABLE 104.PERKINELMER: COMPANY SNAPSHOT
TABLE 105.PERKINELMER: OPERATING SEGMENT
TABLE 106.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 107.QIAGEN: COMPANY SNAPSHOT
TABLE 108.QIAGEN: PRODUCT SEGMENT
TABLE 109.PFIZER: PRODUCT PORTFOLIO
TABLE 110.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 111.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
TABLE 112.SANOFI: PRODUCT PORTFOLIO
TABLE 113.ZYMO RESEARCH: COMPANY SNAPSHOT
TABLE 114.ZYMO RESEARCH: OPERATING SEGMENTS
TABLE 115.ZYMO RESEARCH: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.EPIGENETICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2019
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018–2020
FIGURE 05.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2020
FIGURE 06.TOP WINNING STRATEGIES, BY COMPANY, 2018–2020
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.LOW THREAT OF SUBSTITUTION
FIGURE 11.HIGH COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.CHIP SEQUENCING KITS MARKET, 2019–2027 ($MILLION)
FIGURE 14.BISULFITE CONVERSION KITS MARKET, 2019–2027 ($MILLION)
FIGURE 15.WHOLE GENOME AMPLIFICATION KITS MARKET, 2019–2027 ($MILLION)
FIGURE 16.5-HMC & 5-MC ANALYSIS KITS MARKET, 2019–2027 ($MILLION)
FIGURE 17.RNA SEQUENCING KITS MARKET, 2019–2027 ($MILLION)
FIGURE 18.OTHERS MARKET, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS EPIGENETICS KITS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.ANTIBODIES MARKET, 2019–2027 ($MILLION)
FIGURE 21.MAGNETIC BEADS MARKET, 2019–2027 ($MILLION)
FIGURE 22.HISTONES MARKET, 2019–2027 ($MILLION)
FIGURE 23.BUFFERS MARKET, 2019–2027 ($MILLION)
FIGURE 24.PRIMERS MARKET, 2019–2027 ($MILLION)
FIGURE 25.OTHERS MARKET, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS EPIGENETICS REAGENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 27.DNA POLYMERASES MARKET, 2019–2027 ($MILLION)
FIGURE 28.OTHER DNA-MODIFYING ENZYMES MARKET, 2019–2027 ($MILLION)
FIGURE 29.DNA LIGASES MARKET, 2019–2027 ($MILLION)
FIGURE 30.METHYLTRANSFERASES MARKET, 2019–2027 ($MILLION)
FIGURE 31.ACETYLASES MARKET, 2019–2027 ($MILLION)
FIGURE 32.REVERSE TRANSCRIPTASE MARKET, 2019–2027 ($MILLION)
FIGURE 33.OTHER PROTEIN-MODIFYING ENZYMES MARKET, 2019–2027 ($MILLION)
FIGURE 34.RNA LIGASES MARKET, 2019–2027 ($MILLION)
FIGURE 35.OTHER RNA-MODIFYING ENZYMES MARKET, 2019–2027 ($MILLION)
FIGURE 36.COMPARATIVE ANALYSIS EPIGENETICS ENZYMES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 37.NEXT GENERATION SEQUENCERS MARKET, 2019–2027 ($MILLION)
FIGURE 38.QPCRS MARKET, 2019–2027 ($MILLION)
FIGURE 39.MASS SPECTROMETERS MARKET, 2019–2027 ($MILLION)
FIGURE 40.SONICATORS MARKET, 2019–2027 ($MILLION)
FIGURE 41.OTHERS MARKET, 2019–2027 ($MILLION)
FIGURE 42.COMPARATIVE ANALYSIS EPIGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 43.EPIGENETICS MARKET FOR SOLID TUMORS, 2019 - 2027 ($MILLION)
FIGURE 44.EPIGENETICS MARKET FOR LIQUID TUMORS, 2019 - 2027 ($MILLION)
FIGURE 45.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR ONCOLOGY MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 46.EPIGENETICS MARKET FOR METABOLIC DISEASES, 2019 - 2027 ($MILLION)
FIGURE 47.EPIGENETICS MARKET FOR INFECTIOUS DISEASES, 2019 - 2027 ($MILLION)
FIGURE 48.EPIGENETICS MARKET FOR INFLAMMATORY DISEASES, 2019 - 2027 ($MILLION)
FIGURE 49.EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, 2019 - 2027 ($MILLION)
FIGURE 50.EPIGENETICS MARKET FOR OTHERS, 2019 - 2027 ($MILLION)
FIGURE 51.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR NON-ONCOLOGY MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 52.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 53.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 54.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 55.U.S. EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 56.CANADA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 57.MEXICO EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 58.GERMANY EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 59.FRANCE EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 60.UK EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 61.ITALY EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 62.SPAIN EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 63.REST OF EUROPE EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 64.JAPAN EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 65.CHINA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 66.AUSTRALIA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 67.INDIA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 68.SOUTH KOREA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 69.REST OF ASIA-PACIFIC EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 70.LATIN AMERICA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 71.MIDDLE EAST & AFRICA EPIGENETICS MARKET, 2019–2027 ($MILLION)
FIGURE 72.ABCAM: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.ABCAM: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 74.AGILENT: NET SALES, 2017–2019 ($MILLION)
FIGURE 75.AGILENT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 76.AGILENT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 77.ILLUMINA: NET SALES, 2017–2019 ($MILLION)
FIGURE 78.ILLUMINA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 79.ILLUMINA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 80.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 81.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 82.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 83.PERKINELMER: NET SALES, 2017–2019 ($MILLION)
FIGURE 84.PERKINELMER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 85.PERKINELMER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 86.QIAGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 87.QIAGEN: REVENUE SHARE, BY PRODUCT, 2019 (%)
FIGURE 88.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 89.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 90.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 91.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)
$5769
$8995
Add to Cart
Add to Cart
Add to Cart
Add to Cart